Novartis Shuts Down Hydroxychloroquine COVID-19 Clinical Trial

The rapid descent continues for hydroxychloroquine as hope for a cure for COVID-19. On Monday, pharmaceutical giant Novartis (NYSE: NVS) announced that it is stopping the sponsored clinical trial it was conducting on the treatment of COVID-19 with the drug.

The company says this is "due to acute enrollment challenges that have made trial completion infeasible." It stressed that no safety issues had been reported from the study. On the other hand, it reached no conclusions on the drug's efficacy.

Image source: Getty Images.

Continue reading

Source Fool.com